Kestra Advisory Services LLC Sells 1,226 Shares of Stryker Co. (NYSE:SYK)

Kestra Advisory Services LLC decreased its holdings in Stryker Co. (NYSE:SYK) by 1.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 99,096 shares of the medical technology company’s stock after selling 1,226 shares during the quarter. Kestra Advisory Services LLC’s holdings in Stryker were worth $35,763,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. State Street Corp lifted its position in Stryker by 2.2% in the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock valued at $5,279,788,000 after acquiring an additional 316,404 shares in the last quarter. FMR LLC lifted its position in shares of Stryker by 3.0% during the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock worth $2,639,725,000 after buying an additional 215,782 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Stryker by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company’s stock worth $2,484,893,000 after buying an additional 165,490 shares in the last quarter. Parnassus Investments LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $762,798,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Stryker by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,985,045 shares of the medical technology company’s stock worth $714,715,000 after buying an additional 48,819 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 1.7 %

SYK opened at $369.96 on Friday. The company has a fifty day moving average price of $383.04 and a 200-day moving average price of $373.37. The firm has a market capitalization of $141.17 billion, a P/E ratio of 47.68, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company posted $3.46 earnings per share. Equities research analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Analyst Ratings Changes

Several research firms have commented on SYK. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Barclays lifted their target price on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Truist Financial raised their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. Finally, Canaccord Genuity Group raised their price target on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $421.90.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.